Aditxt (ADTX) Competitors $0.93 0.00 (-0.45%) Closing price 09/5/2025 03:59 PM EasternExtended Trading$0.94 +0.01 (+0.56%) As of 09/5/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ADTX vs. ABP, ATNF, AYTU, FNCH, CYCC, IXHL, HOTH, LSB, MBRX, and SYBXShould you be buying Aditxt stock or one of its competitors? The main competitors of Aditxt include Abpro (ABP), 180 Life Sciences (ATNF), Aytu BioPharma (AYTU), Finch Therapeutics Group (FNCH), Cyclacel Pharmaceuticals (CYCC), Incannex Healthcare (IXHL), Hoth Therapeutics (HOTH), LakeShore Biopharma (LSB), Moleculin Biotech (MBRX), and Synlogic (SYBX). These companies are all part of the "pharmaceutical products" industry. Aditxt vs. Its Competitors Abpro 180 Life Sciences Aytu BioPharma Finch Therapeutics Group Cyclacel Pharmaceuticals Incannex Healthcare Hoth Therapeutics LakeShore Biopharma Moleculin Biotech Synlogic Abpro (NASDAQ:ABP) and Aditxt (NASDAQ:ADTX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, media sentiment, dividends, profitability, earnings, analyst recommendations, valuation and institutional ownership. Do insiders & institutionals have more ownership in ABP or ADTX? 23.3% of Abpro shares are owned by institutional investors. Comparatively, 15.5% of Aditxt shares are owned by institutional investors. 20.8% of Abpro shares are owned by company insiders. Comparatively, 0.0% of Aditxt shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is ABP or ADTX more profitable? Abpro has a net margin of 0.00% compared to Aditxt's net margin of -206,431.38%. Abpro's return on equity of 0.00% beat Aditxt's return on equity.Company Net Margins Return on Equity Return on Assets AbproN/A N/A -241.16% Aditxt -206,431.38%-316.98%-80.88% Do analysts prefer ABP or ADTX? Abpro currently has a consensus target price of $4.00, indicating a potential upside of 1,760.47%. Given Abpro's stronger consensus rating and higher probable upside, research analysts clearly believe Abpro is more favorable than Aditxt.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abpro 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Aditxt 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has better earnings & valuation, ABP or ADTX? Abpro has higher revenue and earnings than Aditxt. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAbpro$180K95.76-$7.23MN/AN/AAditxt$130K35.81-$34.45MN/AN/A Which has more volatility & risk, ABP or ADTX? Abpro has a beta of 0.03, indicating that its share price is 97% less volatile than the S&P 500. Comparatively, Aditxt has a beta of 1.51, indicating that its share price is 51% more volatile than the S&P 500. Does the media prefer ABP or ADTX? In the previous week, Abpro's average media sentiment score of 0.00 equaled Aditxt'saverage media sentiment score. Company Overall Sentiment Abpro Neutral Aditxt Neutral SummaryAbpro beats Aditxt on 10 of the 12 factors compared between the two stocks. Get Aditxt News Delivered to You Automatically Sign up to receive the latest news and ratings for ADTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ADTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADTX vs. The Competition Export to ExcelMetricAditxtMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.65M$2.61B$5.82B$9.94BDividend YieldN/A50.05%6.70%4.53%P/E RatioN/A23.1476.2126.11Price / Sales35.81751.14557.45121.74Price / CashN/A26.7025.7029.11Price / Book-0.625.5011.486.09Net Income-$34.45M$32.95M$3.29B$266.19M7 Day Performance-9.24%2.88%1.28%0.45%1 Month Performance-23.38%9.38%8.56%5.05%1 Year Performance-99.98%2.44%61.19%26.04% Aditxt Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADTXAditxtN/A$0.93-0.4%N/A-100.0%$4.65M$130K0.0060Positive NewsABPAbproN/A$0.25-1.6%$4.00+1,532.0%N/A$19.96M$180K0.0015Gap DownATNF180 Life Sciences0.3069 of 5 stars$3.30-31.4%N/A+18.5%$19.93MN/A-0.227Positive NewsHigh Trading VolumeAYTUAytu BioPharma3.9122 of 5 stars$2.30+4.5%$10.00+334.8%-5.9%$19.75M$81M-3.19160Short Interest ↓Gap UpFNCHFinch Therapeutics Group0.4791 of 5 stars$12.00-11.0%N/AN/A$19.27MN/A-1.36190Short Interest ↑CYCCCyclacel Pharmaceuticals1.258 of 5 stars$7.55-5.5%N/A-97.2%$17.89M$40K-0.0114Positive NewsAnalyst DowngradeShort Interest ↓IXHLIncannex Healthcare0.5393 of 5 stars$0.74+25.9%N/A-68.4%$17.31M$10K-0.613Short Interest ↓Gap DownHigh Trading VolumeHOTHHoth Therapeutics2.4789 of 5 stars$1.25-3.9%$4.00+220.1%+25.5%$17.24MN/A-1.174LSBLakeShore Biopharma1.4615 of 5 stars$0.82-0.7%N/A-81.0%$17.22M$85.67M0.00773Positive NewsShort Interest ↓Gap DownMBRXMoleculin Biotech3.1595 of 5 stars$0.57+1.3%$4.00+595.9%-84.4%$17.19MN/A0.0020Analyst RevisionGap DownSYBXSynlogicN/A$1.48+1.4%N/A+0.7%$17.08M$10K-18.5080 Related Companies and Tools Related Companies Abpro Alternatives 180 Life Sciences Alternatives Aytu BioPharma Alternatives Finch Therapeutics Group Alternatives Cyclacel Pharmaceuticals Alternatives Incannex Healthcare Alternatives Hoth Therapeutics Alternatives LakeShore Biopharma Alternatives Moleculin Biotech Alternatives Synlogic Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADTX) was last updated on 9/7/2025 by MarketBeat.com Staff From Our PartnersWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredBuffett, Gates and Bezos Dumping StocksThe world's wealthiest individuals are making huge moves with their money. Warren Buffett just liquidated b...Banyan Hill Publishing | Sponsored“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredTurn $1K into $50K with This DeFi GemBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aditxt, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aditxt With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ADTX Stock Alerts